Gur Roshwalb

Gur A. Roshwalb is currently a Director at KAHR Medical Ltd., Biosplice Therapeutics, Inc., MiNA Therapeutics Ltd., Viracta Subsidiary, Inc., and Altrubio, Inc. He previously served as the Chief Executive Officer of Celsus Therapeutics Plc from 2013 to 2015.
He was also the President & Chief Executive Officer of Zywie LLC.
From 2013 to 2017, he held the position of Chief Executive Officer & Director at Akari Therapeutics Plc.
Additionally, he has worked as a Director at Sunesis Pharmaceuticals, Inc. and as an Independent Director at Viracta Therapeutics, Inc. from 2021 to 2022.
He has also held positions as Vice President at Venrock Associates and as a Senior Research Analyst at Piper Sandler & Co. (Broker).
He started his career as the Chief Resident at The Mount Sinai Medical Center, Inc. in 1997.
Dr. Roshwalb holds an undergraduate degree from The Trustees of Columbia University in The City of New York, a doctorate from Albert Einstein College of Medicine, Inc., and an MBA from The Leonard N Stern School of Business.